



NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

RADNOR, Pa., April 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, a Delaware Corporation, today announced that it will release its first quarter 2023 financial results after the market closes on Thursday, May 11, 2023, via press release, which will be available on the Company's website at <https://ir.nrxpharma.com/>. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m. ET the same day.

NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

A live webcast of the conference call will be available on the Company's website at <https://ir.nrxpharma.com/news-events/ir-calendar>. An archive of the webcast will be available on the Company's website for 30 days.

Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase 2b/3 clinical trial for suicidal treatment-resistant bipolar depression, which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company's prior Phase 2 STABIL-B clinical trial evaluating NRX-101 in patients with Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) demonstrated a substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. Based on the findings from the STABIL-B trial, the U.S. Food and Drug Administration (FDA) granted a Special Protocol Agreement and Breakthrough Therapy Designation for NRX-101 in patients with Severe Bipolar Depression with ASIB.

SOURCE NRx Pharmaceuticals, Inc.

For further information: CORPORATE CONTACT: Matthew Duffy, Chief Business Officer, mduffy@nrxpharma.com;
INVESTOR RELATIONS: Suzanne Messere, Investor Relations, suzanne.messere@sternir.com

View original content to download multimedia <https://ir.nrxpharma.com/2023-04-27-NRx-Pharmaceuticals-to-Report-First-Quarter-2023-Financial-Results-on-May-11,-2023>